Relatlimab
| Relatlimab | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Relatlimab is an experimental immunotherapy drug developed for the treatment of various types of cancer. It is a monoclonal antibody that targets the lymphocyte-activation gene 3 (LAG-3), an immune checkpoint receptor expressed on the surface of T-cells. By inhibiting LAG-3, Relatlimab aims to enhance the immune system's ability to fight cancer.
Mechanism of Action[edit]
Relatlimab functions by binding to the LAG-3 receptor on T-cells. LAG-3 is involved in regulating the immune response, and its activation can diminish the ability of T-cells to combat cancer cells effectively. By blocking this receptor, Relatlimab may help in restoring and amplifying the immune response against cancer cells.
Clinical Trials[edit]
Relatlimab has been evaluated in several clinical trials, often in combination with other immunotherapeutic agents such as nivolumab, a PD-1 inhibitor. These studies aim to determine the efficacy and safety of Relatlimab in treating various malignancies, including melanoma, non-small cell lung cancer (NSCLC), and more.
Development and Regulatory Status[edit]
As of the last update, Relatlimab is still under clinical investigation and has not yet received approval from regulatory bodies such as the Food and Drug Administration (FDA) for general medical use. Ongoing trials continue to assess its potential as a viable cancer treatment.
See Also[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
